As of Nov 27
| +0.37 / +2.86%|
The 2 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 15.50, with a high estimate of 21.00 and a low estimate of 10.00. The median estimate represents a +16.63% increase from the last price of 13.29.
The current consensus among 4 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.